Rho Associated Protein Kinase 2 - Pipeline Review, H2 2019
Rho Associated Protein Kinase 2 - Pipeline Review, H2 2019
SUMMARY
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation.
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 11 respectively. Report covers products from therapy areas Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Cardiovascular, Immunology, Ophthalmology, Central Nervous System, Metabolic Disorders, Musculoskeletal Disorders, Non Malignant Disorders and Oncology which include indications Idiopathic Pulmonary Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Glaucoma, Kidney Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Stroke, Acute Renal Failure (ARF) (Acute Kidney Injury), Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma), Chronic Obstructive Pulmonary Disease (COPD), Crohn's Disease (Regional Enteritis), Diabetic Nephropathy, Fibrosis, Graft Versus Host Disease (GVHD), Inflammation, Liver Fibrosis, Pain, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Solid Tumor and Systemic Sclerosis (Scleroderma).
The latest report Rho Associated Protein Kinase 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation.
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 11 respectively. Report covers products from therapy areas Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Cardiovascular, Immunology, Ophthalmology, Central Nervous System, Metabolic Disorders, Musculoskeletal Disorders, Non Malignant Disorders and Oncology which include indications Idiopathic Pulmonary Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Glaucoma, Kidney Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Stroke, Acute Renal Failure (ARF) (Acute Kidney Injury), Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma), Chronic Obstructive Pulmonary Disease (COPD), Crohn's Disease (Regional Enteritis), Diabetic Nephropathy, Fibrosis, Graft Versus Host Disease (GVHD), Inflammation, Liver Fibrosis, Pain, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Solid Tumor and Systemic Sclerosis (Scleroderma).
The latest report Rho Associated Protein Kinase 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)
- The report reviews Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Overview
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Theratrophix LLC
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Drug Profiles
ANG-4201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-13148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-2017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-08397 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-8087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Metabolic Disorders, Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROCK1 and ROCK 2 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Dormant Products
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Discontinued Products
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: BioAxone BioSciences expands patent for treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho kinase inhibitors
Dec 03, 2019: Kadmon to present updated data from phase 2 study of KD025 in cGVHD at the 61st ASH Annual Meeting & Exposition
Nov 19, 2019: Redx Pharma and Medicines Discovery Catapult awarded grant for biomarker project including Small Molecule to Inhibit ROCK2 for Fibrotic Diseases
Sep 12, 2019: BioAxone BioSciences announces publication in Translational Stroke Research of Cavernous Angioma Disease Research Article
Aug 13, 2019: Kadmon fully enrolls pivotal trial of KD025 for Chronic Graft-Versus-Host Disease
Aug 13, 2019: Kadmon fully enrolls pivotal trial of KD025 for Chronic Graft-Versus-Host Disease
Jul 09, 2019: Kadmon doses first patient in phase 2 clinical trial of KD025 in Systemic Sclerosis
Feb 12, 2019: Redx Pharma: New in vivo data suggests ROCK2 has broad potential in fibrosis
Dec 03, 2018: Kadmon announces updated findings from ongoing phase 2 clinical trial of KD025 in cGVHD at ASH Annual Meeting
Nov 29, 2018: Kadmon presents data on New ROCK Inhibitor clinical candidate at Anti-Fibrotic Drug Development Summit
Nov 01, 2018: Kadmon announces oral presentation on KD025 in Chronic Graft-Versus-Host Disease at ASH Annual Meeting
Oct 26, 2018: Redx announces details from the ROCK2 inhibitor poster presented at the ASN Kidney Week 2018 in San Diego
Oct 25, 2018: Kadmon initiates pivotal phase 2 trial of KD025 in chronic graft-versus-host disease
Oct 22, 2018: Redx ROCK2 inhibitors poster to be presented at the ASN Kidney Week 2018 in San Diego
Oct 17, 2018: FDA grants breakthrough therapy designation to Kadmon's KD025 for chronic graft-versus-host disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Overview
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Theratrophix LLC
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Drug Profiles
ANG-4201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-13148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-2017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-08397 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-8087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Metabolic Disorders, Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROCK1 and ROCK 2 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Dormant Products
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Discontinued Products
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: BioAxone BioSciences expands patent for treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho kinase inhibitors
Dec 03, 2019: Kadmon to present updated data from phase 2 study of KD025 in cGVHD at the 61st ASH Annual Meeting & Exposition
Nov 19, 2019: Redx Pharma and Medicines Discovery Catapult awarded grant for biomarker project including Small Molecule to Inhibit ROCK2 for Fibrotic Diseases
Sep 12, 2019: BioAxone BioSciences announces publication in Translational Stroke Research of Cavernous Angioma Disease Research Article
Aug 13, 2019: Kadmon fully enrolls pivotal trial of KD025 for Chronic Graft-Versus-Host Disease
Aug 13, 2019: Kadmon fully enrolls pivotal trial of KD025 for Chronic Graft-Versus-Host Disease
Jul 09, 2019: Kadmon doses first patient in phase 2 clinical trial of KD025 in Systemic Sclerosis
Feb 12, 2019: Redx Pharma: New in vivo data suggests ROCK2 has broad potential in fibrosis
Dec 03, 2018: Kadmon announces updated findings from ongoing phase 2 clinical trial of KD025 in cGVHD at ASH Annual Meeting
Nov 29, 2018: Kadmon presents data on New ROCK Inhibitor clinical candidate at Anti-Fibrotic Drug Development Summit
Nov 01, 2018: Kadmon announces oral presentation on KD025 in Chronic Graft-Versus-Host Disease at ASH Annual Meeting
Oct 26, 2018: Redx announces details from the ROCK2 inhibitor poster presented at the ASN Kidney Week 2018 in San Diego
Oct 25, 2018: Kadmon initiates pivotal phase 2 trial of KD025 in chronic graft-versus-host disease
Oct 22, 2018: Redx ROCK2 inhibitors poster to be presented at the ASN Kidney Week 2018 in San Diego
Oct 17, 2018: FDA grants breakthrough therapy designation to Kadmon's KD025 for chronic graft-versus-host disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Angion Biomedica Corp, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by BioAxone BioSciences Inc, H2 2019
Pipeline by HitGen LTD, H2 2019
Pipeline by Kadmon Corp LLC, H2 2019
Pipeline by Redx Pharma Plc, H2 2019
Pipeline by Theratrophix LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Angion Biomedica Corp, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by BioAxone BioSciences Inc, H2 2019
Pipeline by HitGen LTD, H2 2019
Pipeline by Kadmon Corp LLC, H2 2019
Pipeline by Redx Pharma Plc, H2 2019
Pipeline by Theratrophix LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Theratrophix LLC
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Theratrophix LLC
